Current status of second-line therapy for metastatic colorectal cancer.

摘要: Decisions regarding the optimal systemic therapy for patients with metastatic colorectal cancer (CRC) have become more complex identification and development of multiple effective agents this disease. Multiple treatment options are now available in second-line setting CRC who progressed despite prior chemotherapy. The exact choice depends on first-line that was administered. Irinotecan as a salvage progression following front-line 5-fluorouracil (5-FU)-based therapies confirmed number phase II/III studies. Many received irinotecan/5-FU-based benefit from combination oxaliplatin 5-FU/leucovorin (FOLFOX) terms response, time to progression, relief tumor-related symptoms. Other considerations include integration targeted into chemotherapy regimens. results randomized II trial demonstrated addition cetuximab irinotecan irinotecan-resistant tumors represents another active option these patients. activity bevacizumab part is currently under investigation III trials expected within next year. In summary, availability 5 drugs provides us, first time, choice--and dilemma--regarding CRC.